Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States

Autor: W. Ray Kim, Laura E. Telep, Belinda Jump, Mei Lu, Heribert Ramroth, John Flaherty, Anuj Gaggar, Anand P. Chokkalingam, Stuart C. Gordon

Publikováno v: Alimentary Pharmacology & Therapeutics. 55:828-835

Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the first-line treatment agents for chronic hepatitis B virus (HBV). Recently, whether the degree to which the risk of hepatocellular carcinoma (HCC) may be reduced by ETV vs TDF has been de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d4a53fd77b594ec7aec86878b04a2d
https://doi.org/10.1111/apt.16786

Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment

Autor: Mark Sulkowski, Laura E. Telep, Massimo Colombo, Francois Durand, K. Rajender Reddy, Eric Lawitz, Marc Bourlière, Nelson Cheinquer, Stacey Scherbakovsky, Liyun Ni, Lindsey Force, Heribert Ramroth, Anuj Gaggar, Anand P. Chokkalingam, Meghan E. Sise

Publikováno v: Alimentary Pharmacology & Therapeutics (Suppl)
Alimentary Pharmacology & Therapeutics (Suppl), 2022, 55 (9), pp.1169-1178. ⟨10.1111/apt.16830⟩

Background: Sofosbuvir, a prodrug nucleoside inhibitor of hepatitis C virus, has a predominant circulating metabolite that is renally eliminated. Whether sofosbuvir is associated with chronic kidney disease (CKD) progression is not well understood.Me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3f47067c4c65c4697a03002ab8a4405
https://www.hal.inserm.fr/inserm-04050685/document